A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs GSK 239512 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 18 Nov 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 18 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.